[March 27, 2014]

VeriTeQ Rebrands its "Q Inside SmartMarker" to Lead its Radiation Dosimetry Business; Q Inside Smart Marker is World's First Implantable Sensor Cleared by FDA to Measure Radiation Dose Directly at the Tumor Site

VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it is rebranding its Q Inside SmartMarker to lead its radiation dosimetry business. Q Inside SmartMarker (previously known as DVS SmartMarker®) is the only FDA- cleared implantable radio frequency ("RF") radiation sensor that provides localization of a tumor and measures radiation dose at the tumor site. VeriTeQ's radiation dosimetry products have six FDA clearances and CE approvals, and the Company has over 100 patents, patents pending, and exclusive licenses.

Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician's plan, as even a small deviation from planned dose can have a significant impact on patient survival rates.

Scott R. Silverman, Chairman and CEO of VeriTeQ, stated, "Radiation under-dosing and, perhaps more importantly, radiation overdosing have been a top concernof the medical community for years. Confirming the delivered dose of radiation is known to have a direct and significant impact on treatment efficacy and patient survival rates, and our Q Inside SmartMarker can support healthcare providers with this potentially life-saving data."

According to the ECRI Institute, radiation or CT overdose make the list of the Top 10 Technology Hazards each year going back at least eight years. These hazards include radiation overdose and other errors during radiation therapy; unnecessary exposures and radiation burns from diagnostic radiology procedures; and exposure hazards from radiation therapy and CT.

Q Inside SmartMarker is compatible with a large variety of commercially available systems including, but not limited to, CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens (News - Alert) MV CBCT, and Resonant Medical.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release about our future expectations, including that the Company's Q Inside SmartMarker will lead its radiation dosimetry business, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ's Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

[ Back To TMCnet.com's Homepage ]